![United States: Biocon Settles With Janssen, Securing U.S. Market Entry Date For Ustekinumab Biosimilar - Goodwin Procter LLP](https://cdn.newsserve.net/ONPglobe256.png)
United States: Biocon Settles With Janssen, Securing U.S. Market Entry Date For Ustekinumab Biosimilar - Goodwin Procter LLP
On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson ("J&J") regarding Bmab 1200, Biocon's proposed biosimilar to STELARA.
Full Article